EUVIMEDEUVIMED entdecken
Multizentrische Studie

Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study)

Atsushi Nakamura, Ou Yamaguchi, Keita Mori, Keita Miura, Motohiro Tamiya, Tomohiro Oba, Noriko Yanagitani, Hideaki Mizutani, Takashi Ninomiya, Tomosue Kajiwara, Kentaro Ito, Akihiko Miyanaga und 4 weitere

European Journal of Cancer · 2023

DOI: 10.1016/j.ejca.2023.01.025 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2023. Verfasst von Atsushi Nakamura und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan. Hauptthemen laut MEDLINE: Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Eli Lilly Japan, Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Ramucirumab plus docetaxel (RD) is a promising treatment for previously treated advanced non-small cell lung cancer (NSCLC). However, its clinical significance after platinum-based chemotherapy plus programmed death-1 (PD-1) blockade remains unclear. RESEARCH QUESTION: What is the clinical significance of RD as a second-line treatment after the failure of chemo-immunotherapy in NSCLC? STUDY DESIGN AND METHODS: In this multicentre retrospective study, 288 patients with advanced NSCLC who received RDas second-line therapy after platinum-based chemotherapy plus PD-1 blockade, at 62 Japanese institutions from January 2017 to August 2020, were included. Prognostic analyses were performed using the log-rank test. Prognostic factor analyses were performed using a Cox regression analysis. RESULTS: A total of 288 patients were enrolled: 222 were men (77.1%), 262 were aged

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenocarcinomaCarcinoma, Non-Small-Cell LungLung NeoplasmsFemaleHumansMaleAntineoplastic Combined Chemotherapy ProtocolsDocetaxelPlatinumRetrospective StudiesTaxoidsRamucirumabProgrammed Cell Death 1 Receptor

Stichwörter der Autor:innen

Chemo-immunotherapyNon-small cell lung cancerRamucirumab plus docetaxelSecond-line treatmentVEGFR2

Substanzen

DocetaxelPlatinumTaxoidsRamucirumabPDCD1 protein, humanProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
  • Department of Respiratory Medicine, Comprehensive Cancer Center, Saitama Medical University International Medical Center, Hidaka, Japan. Electronic address: ouyamagu@saitama-med.ac.jp.
  • Clinical Research Center, Shizuoka Cancer Center, Nagaizumi, Japan.
  • Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
  • Department of Respiratory Medicine, Saitama Red Cross Hospital, Saitama, Japan.

Förderung

  • Eli Lilly Japan
  • Eli Lilly and Company

Zitieren

APA

Nakamura, A., Yamaguchi, O., Mori, K., Miura, K., Tamiya, M., Oba, T., Yanagitani, N., Mizutani, H., Ninomiya, T., Kajiwara, T., Ito, K., Miyanaga, A., Arai, D., Kodama, H., Kobayashi, K., & Kaira, K. (2023). Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study). European Journal of Cancer. https://doi.org/10.1016/j.ejca.2023.01.025

Vancouver

Nakamura A, Yamaguchi O, Mori K, Miura K, Tamiya M, Oba T, et al. Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study). European Journal of Cancer. 2023. doi:10.1016/j.ejca.2023.01.025

BibTeX
@article{Nakamura2023,
  author = {Nakamura, Atsushi and Yamaguchi, Ou and Mori, Keita and Miura, Keita and Tamiya, Motohiro and Oba, Tomohiro and Yanagitani, Noriko and Mizutani, Hideaki and Ninomiya, Takashi and Kajiwara, Tomosue and Ito, Kentaro and Miyanaga, Akihiko and Arai, Daisuke and Kodama, Hiroaki and Kobayashi, Kunihiko and Kaira, Kyoichi},
  title = {Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study)},
  journal = {European Journal of Cancer},
  year = {2023},
  doi = {10.1016/j.ejca.2023.01.025}
}
Kostenlos starten →